Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy
about
Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathyPharmacological treatment of primary membranous nephropathy in 2016.Treatment pattern in patients with idiopathic membranous nephropathy-practices in Sweden at the start of the millenniumOverview of current and alternative therapies for idiopathic membranous nephropathy.Membranous nephropathy: thinking through the therapeutic options.Primary Membranous Nephropathy.Renal Phospholipase A2 Receptor and the Clinical Features of Idiopathic Membranous Nephropathy.Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome.Treatment of membranous nephropathy: time for a paradigm shift.Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.Clinical and histopathologic profile of patients with primary IgA nephropathy seen in a tertiary hospital in India.Long-term outcomes of persistent disease and relapse in primary membranous nephropathy.Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy.Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as prognostic markers in idiopathic membranous nephropathy.Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management.Traditional Chinese Medicine for Refractory Nephrotic Syndrome: Strategies and Promising Treatments.
P2860
Q33715801-BFDB6529-EA02-4FE5-8EA5-9BACD9218515Q34008949-33A0C72E-A456-4E48-81F2-9B4D18A76EE1Q36106413-7A790F73-A928-4233-B0FE-3AD62ED01E78Q36689205-4A4C5B91-25B4-4658-8B03-5476A304A7F2Q38425865-0B57DCEA-2C8D-471A-AA16-DCF4E4AC1D56Q38733002-D9FD78EC-419C-4C67-89CA-21F0239CB962Q38760741-A745073B-A2FC-43D5-AC43-486CA59BBE37Q38842914-AA42C92E-17E6-4A0D-8D3D-610B83C39BEDQ39335899-A6DAE5BF-D209-4729-ADDF-95862D8984F9Q39410091-6465521A-929F-4DFA-A5DE-4871C99DA5ADQ39648546-CE7715D3-9FB9-4E1B-ABB2-668601FFD899Q40030962-E35AA466-450D-4C84-959D-827493180894Q40105860-9EDC47EA-6479-4B19-875D-E05F7EC7D4BDQ40208466-4429FA7F-12DF-4ACF-931C-D78BA47BECEDQ41123392-E5FCD87D-2D07-4D4A-8F98-310D5223AFDAQ42155627-8F3C9175-4900-4591-B4ED-03D2D4476F57Q52670774-E940B93A-0914-4D81-B0D7-088D451B2AFBQ55005671-C08BAA34-650F-4F7E-806A-F01BACFC47E2
P2860
Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term outcomes in idiopath ...... restrictive treatment strategy
@en
Long-term outcomes in idiopath ...... estrictive treatment strategy.
@nl
type
label
Long-term outcomes in idiopath ...... restrictive treatment strategy
@en
Long-term outcomes in idiopath ...... estrictive treatment strategy.
@nl
prefLabel
Long-term outcomes in idiopath ...... restrictive treatment strategy
@en
Long-term outcomes in idiopath ...... estrictive treatment strategy.
@nl
P2093
P2860
P356
P1476
Long-term outcomes in idiopath ...... restrictive treatment strategy
@en
P2093
Jack F M Wetzels
Jan A J G van den Brand
Julia M Hofstra
Peter R van Dijk
P2860
P304
P356
10.1681/ASN.2013020185
P577
2013-09-12T00:00:00Z